CN code 293359 covers other compounds containing an unfused pyrimidine ring not elsewhere specified in Chapter 29. Key substances classified here include pyrimidine (1,3-diazine) itself and its chemically defined derivatives - thymine (5-methyluracil, CAS 65-71-4), cytosine (4-aminopyrimidin-2(1H)-one, CAS 71-30-7), uracil, orotic acid and related pure heterocyclic bases. Thymine and cytosine are nucleobases that form integral components of DNA and RNA respectively, giving substances in this subheading significant importance in biotechnology, pharmaceutical synthesis and scientific research. In accordance with Note 1 to Chapter 29 of the Combined Nomenclature, classification here requires a chemically defined compound in pure form or in aqueous solution. Mixtures of pyrimidine derivatives formulated for specific end uses may be classified outside Chapter 29 depending on their composition and presentation. Classification is carried out using the General Interpretative Rules of the CN, in particular GIR 1 and GIR 6 for subheadings.

Substances classified under CN 293359 and imported into the European Union are subject to the full requirements of REACH Regulation (EC) No 1907/2006. The importer or an Only Representative (OR) established in the EU must ensure each substance is registered with the European Chemicals Agency (ECHA) at the appropriate tonnage band before it is placed on the EU market. Substances imported in quantities exceeding one tonne per year require registration. CLP labelling must reflect current toxicological and ecotoxicological data; thymine and cytosine are not generally classified as substances of very high concern, but other pyrimidine derivatives require individual hazard assessment. A Safety Data Sheet (SDS) compliant with Regulation (EU) 2020/878 must be provided to recipients in the official language of the destination member state. Substances intended for pharmaceutical manufacturing or use in medicinal products are additionally subject to GMP requirements and pharmacopoeial standards. Certain antiviral or cytostatic pyrimidine derivatives may be subject to national controlled substance legislation in the member state of destination.

When importing substances under CN 293359, the customs declaration should specify the IUPAC name, CAS number, degree of chemical purity and the REACH registration number or confirmation of Only Representative appointment. For substances intended for use as active pharmaceutical ingredients (APIs), GMP certificates and EU Pharmacopoeia or ICH Q7 compliance documentation may be required by customs or the competent authority. Export of pyrimidine derivatives to third countries should be verified against Regulation (EU) 2021/821 on dual-use export controls, particularly for substances that could serve as precursors in the synthesis of medicinal products or biological materials. Importers should consult the European Commission TARIC database for current MFN duty rates and available tariff preferences under FTA agreements or the Generalised Scheme of Preferences (GSP). EUR.1 movement certificates or invoice declarations enable preferential rates for qualifying countries of origin. Anti-dumping or countervailing measures for this subheading should be verified in TARIC prior to each transaction.

Organic substances under CN code 2933 59 (Compounds with pyrimidine ring) require detailed chemical documentation for customs clearance. The Safety Data Sheet must comply with REACH Annex II. Substances classified as hazardous under CLP require GHS pictogram labelling. Transport follows ADR (road) or IMDG (maritime) regulations. Some organic substances may be subject to export controls as dual-use goods. Importers should verify whether the substance requires REACH authorisation (Annex XIV) or is subject to restrictions (Annex XVII).